Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence - Wikidata - wikimedia - TriplyDB

Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence

Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence

http://www.wikidata.org/entity/Q36248498

about

National consensus in China on diagnosis and treatment of patients with advanced breast cancer Triple negative breast cancer: looking for the missing link between biology and treatments Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials Optimal management of breast cancer in the elderly patient: current perspectives Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients.Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research.Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Inference of synergy/antagonism between anticancer drugs from the pooled analysis of clinical trials Standard of care and promising new agents for triple negative metastatic breast cancer Effect of Unblinding on Participants' Perceptions of Risk and Confidence in a Large Double-Blind Clinical Trial of Chemotherapy for Breast Cancer Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy?Inositol 1, 4, 5-trisphosphate-dependent nuclear calcium signals regulate angiogenesis and cell motility in triple negative breast cancer.Minimal change disease onset observed after bevacizumab administration.Loss of membranous VEGFR1 expression is associated with an adverse phenotype and shortened survival in breast cancer Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment.The VEGF signaling pathway in cancer: the road ahead.Eribulin mesylate in the management of metastatic breast cancer and other solid cancers: a drug review.Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model.Triple-negative breast cancer: investigating potential molecular therapeutic target.Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue?A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).Biology and Management of Patients With Triple-Negative Breast Cancer.Metastatic breast cancer: The Odyssey of personalization.Cardiovascular disease in cancer survivors.Long noncoding RNAs (lncRNAs) in triple negative breast cancer.Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.Antiangiogenic therapy in breast cancer.Addressing overtreatment in breast cancer: The doctors' dilemma.Disrupting Tumor Angiogenesis and "the Hunger Games" for Breast Cancer.An update on first line therapies for metastatic breast cancer.A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer.Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment.Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer.The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials.DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer.

P2860

Q26775621-01A2752A-4B05-48FE-9D6B-4CADCC4C6E91 Q26783122-38CE2164-6D07-43A0-8AD2-FE2179500E5F Q26822432-898C512E-50BD-4D8C-8F06-28719AB8FEC2 Q27690879-15F0F557-D3FB-431F-88AF-C21464BF1F94 Q28555102-A027C664-F4C9-484D-9F2F-E5C800188F3B Q30657829-30A33E60-7733-46A4-9E4B-C42012222292 Q31157714-22FF9BEA-2761-4095-B799-4CAC4B7E647C Q33770680-7B31E8CE-030A-46DE-8AB9-F00C5A4F8B23 Q34768518-7C3D5DEC-6A8A-4994-85BE-144943608AD5 Q34774884-24F1CBCD-4FBE-4846-8DCE-E2499AEC0503 Q35770292-9758DFE2-F440-4C6F-A366-05EB464DD61B Q35815486-BAB5B8E5-2D49-403D-A1D4-B5C2766ED7D9 Q36334094-1A32DEF9-C8F5-4F97-BBC8-674270D6101E Q36689167-1331F2BA-A0D3-41D7-91D4-92B0A9492718 Q37083038-5FF0005E-1346-449B-BA8E-8A79B34059CD Q37221629-C8794F94-8281-45A9-B6C0-87EC5D44F333 Q37354128-2093ECE6-022A-4E10-A2FD-4E9EFC04D31D Q38213846-C766A675-027A-4660-9A61-8696056BC490 Q38245841-DD28FC2D-1E8B-4C69-8B1D-E1F709FDD1EB Q38259322-0B398ED3-FA13-4CD8-BC8C-1E39B45A85B8 Q38322346-26FEA036-FB10-403A-A05A-CDDE2B4C4CF5 Q38661921-DFB85C1B-48BB-493B-BEA2-5CAA22D6CDB5 Q38893074-651DE11F-469D-4601-A199-6394298D02D7 Q38901163-D00D9F55-8996-46EA-86FB-CDB09C741A8C Q39103481-BB5E9A83-D45A-40AF-8559-33B1673EABBB Q39110866-7236509E-3CA0-4553-9A26-AD8D27765827 Q39582320-EA5B778D-EF2D-4288-A176-F47D8DE7F94A Q47111400-A65CCD81-41AE-4E48-A036-AF7F3E2E62E3 Q47993032-DA4220EF-87BF-473C-85E8-68F1DE33DC4D Q49544357-74EC9CDA-E730-4CA3-A16C-CA5E628576A8 Q50040088-008F0ECD-5211-421C-8CAA-F319C82CEE25 Q51319007-C8B1FFEA-7B05-417B-BF41-2F753989529F Q52664052-9656EE88-F4A9-490C-ABB2-C456A4F5A2FB Q54196655-CE5B975A-3CE5-423C-9722-2A44C1835FFD Q54310257-8B4A98A0-76D2-4472-B279-EFE824A45F73 Q55332979-E3B39385-E3B2-4ADE-8523-2DFA7CD4B98B

P2860

Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence

http://www.wikidata.org/entity/Q36248498

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Bevacizumab and Breast Cancer: ...... ppraisal of Available Evidence

@ast

Bevacizumab and Breast Cancer: ...... ppraisal of Available Evidence

@en

type

label

Bevacizumab and Breast Cancer: ...... ppraisal of Available Evidence

@ast

Bevacizumab and Breast Cancer: ...... ppraisal of Available Evidence

@en

prefLabel

Bevacizumab and Breast Cancer: ...... ppraisal of Available Evidence

@ast

Bevacizumab and Breast Cancer: ...... ppraisal of Available Evidence

@en

P1433

Q36248498-921471A2-7851-4B51-A83E-BE4336CCBD54

P1476

Q36248498-BFFDA6AD-8FEA-4CF7-99CF-6A3BEF83178A

P2093

Q36248498-2077BE78-B4BF-429B-B7CD-1F9FAA726E51

Q36248498-234D7EF0-BD23-48C1-AD62-B9BAC1D0FC06

Q36248498-47F14C63-F500-480E-8941-6F3DC3230391

Q36248498-C2B78745-353E-4FA5-9BA1-31443DF066A8

Q36248498-D5CE7A78-0B78-4308-B5B6-96543744F5D4

P2860

Q36248498-18B3D460-1DB4-4F1D-BE2D-8633BE9CE997

Q36248498-1DC2C9F7-040A-4671-8C95-28E027B0CDAD

Q36248498-1E1B65E3-3838-4799-AAF6-C4925075E316

Q36248498-272E7CAA-8CC9-4BE4-834D-8C95C3448457

Q36248498-285C7FD0-FD21-4BBE-AF71-A7708879943E

Q36248498-2F43C298-9584-496E-8506-7C59BC8C2F8F

Q36248498-346515E0-0EF6-41CE-B2F3-BE38A48262B1

Q36248498-4DA12603-BA3F-40A8-A692-DCF50A964575

Q36248498-543E5AA5-4794-481F-8A86-5DD41F8ED33E

Q36248498-577DF7D3-8AF9-449E-B166-88E5F5D8B00A

P304

Q36248498-AE898086-14B5-4043-A556-3FCEBAC0A91C

P31

Q36248498-62036585-4CEE-4D88-8A78-20566E881866

P356

Q36248498-17530689-4F19-4DA0-A46C-1149BD3DDAC6

P478

Q36248498-260D025F-B66A-4081-83FC-9DFBCDCD4421

P50

Q36248498-E572F29B-E2D4-4DE5-B978-590DCAA1A462

Q36248498-E634A581-78F7-4080-AF67-6DF7661330A5

P577

Q36248498-995817AC-123E-43AF-B39C-9C0A799B9A5E

P5875

Q36248498-D01FB289-8530-4324-B444-BBCCD4DD367A

P698

Q36248498-5426BDA1-DA68-46F3-80F3-E96A169D1C56

P921

Q36248498-1DDC3251-67F0-47E1-A25E-937BA52E4A7D

P932

Q36248498-A899321C-A614-4F61-B8C2-38A00A9290DF

P356

P1433

Journal of oncology

P1476

Bevacizumab and Breast Cancer: ...... ppraisal of Available Evidence

@en

P2093

Alessandra Gennari

http://www.w3.org/2001/XMLSchema#string

José R Rossari

http://www.w3.org/2001/XMLSchema#string

Kamal S Saini

http://www.w3.org/2001/XMLSchema#string

Marianne Paesmans

http://www.w3.org/2001/XMLSchema#string

Otto Metzger-Filho

http://www.w3.org/2001/XMLSchema#string

P2860

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

Measuring inconsistency in meta-analyses

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis.

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

P304

417673

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2012/417673

http://www.w3.org/2001/XMLSchema#string

P478

2012

http://www.w3.org/2001/XMLSchema#string

P50

Evandro de Azambuja

Martine Piccart-Gebhart

P577

2012-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

231176695

http://www.w3.org/2001/XMLSchema#string

P698

23008712

http://www.w3.org/2001/XMLSchema#string

P921

P932

3447373

http://www.w3.org/2001/XMLSchema#string